Telix Pharmaceuticals to acquire IsoTherapeutics for upto $19m
MELBOURNE: Telix Pharmaceuticals Limited (ASX: TLX), a company developing targeted radiopharmaceuticals for cancer diagnosis and therapy, announced today that it has agreed to acquire IsoTherapeutics Group, LLC, a Texas-based firm that specializes in radiochemistry and bioconjugation. IsoTherapeutics, founded in 2005,…